Quick Answer
Lineage Cell Therapeutics, Inc. reported Cash and Equivalents of $40.79 million for fiscal year 2025.
Lineage Cell Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $40.79M | -10.9% |
| 2024 | $45.79M | +29.2% |
| 2023 | $35.44M | +212.1% |
| 2022 | $11.36M | -79.6% |
| 2021 | $55.74M | +71.1% |
| 2020 | $32.59M | +243.1% |
| 2019 | $9.50M | -59.7% |
| 2018 | $23.59M | -36.0% |
| 2017 | $36.84M | +66.8% |
| 2016 | $22.09M | -47.7% |
| 2015 | $42.23M | +43.2% |
| 2014 | $29.49M | +436.5% |
| 2013 | $5.50M | +26.3% |
| 2012 | $4.35M | -80.4% |
| 2011 | $22.21M | -33.3% |
| 2010 | $33.32M | +173.4% |
| 2009 | $12.19M | +99167.7% |
| 2008 | $12.3K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $40.46M | +45.8% | -4.3% |
| June 30, 2025 | $42.27M | +42.7% | -11.7% |
| March 31, 2025 | $47.89M | +9.9% | +4.6% |
| December 31, 2024 | $45.79M | +29.2% | +65.0% |
| September 30, 2024 | $27.75M | -11.8% | -6.3% |
| June 30, 2024 | $29.62M | -12.6% | -32.0% |
| March 31, 2024 | $43.58M | +182.0% | +23.0% |
| December 31, 2023 | $35.44M | +212.1% | +12.6% |
- Lineage Cell Therapeutics, Inc. showed a decrease of -10.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Lineage Cell Therapeutics, Inc.’s cash and equivalents has grown by 332101.3% (from $12.3 thousand to $40.79 million).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: